SAN DIEGO—(BUSINESS WIRE)—May 5, 2008—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced theelection of Laura A. Brege to its board of directors. Ms. Brege willfill a vacancy on the Board and serve as a Class III director. Theterms of the Class III directors expire at the annual meeting ofstockholders in 2010.
"We are delighted that Laura Brege has joined ACADIA's board,"said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. "Herstrong blend of financial, operational, and industry experience willbe a valuable asset as we continue to advance our pipeline of drugcandidates and position them for commercial success."
Ms. Brege is Executive Vice President and Chief Operating Officerof Onyx Pharmaceuticals, Inc. where she is responsible for sales andmarketing, medical affairs, legal, business development, andcompliance functions. She joined Onyx in June 2006 as Executive VicePresident and Chief Business Officer and was promoted to her currentposition in October 2007. Before joining Onyx, Ms. Brege was a generalpartner at Red Rock Management, a venture capital firm. Prior to RedRock, she was Senior Vice President and Chief Financial Officer at CORTherapeutics. Earlier in her career, Ms. Brege served as VicePresident and Chief Financial Officer at Flextronics and VicePresident and Treasurer of The Cooper Companies. Ms. Brege earned herundergraduate degree from Ohio University and has an M.B.A. from theUniversity of Chicago. Ms. Brege also serves on the boards ofAngiotech Pharmaceuticals, Inc. and The Ohio University Foundation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
Forward-Looking Statements
Statements in this press release that are not strictly historicalin nature are forward-looking statements. These statements include butare not limited to statements related to the potential benefits fromthis appointment to ACADIA's pipeline of drug candidates or theircommercial success. These statements are only predictions based oncurrent information and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially fromthose projected in any of such statements due to various factors,including the risks and uncertainties inherent in drug discovery,development and commercialization, and the fact that past results ofclinical trials may not be indicative of future trial results. For adiscussion of these and other factors, please refer to ACADIA's annualreport on Form 10-K for the year ended December 31, 2007 as well asACADIA's subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof.This caution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-lookingstatements are qualified in their entirety by this cautionarystatement and ACADIA undertakes no obligation to revise or update thispress release to reflect events or circumstances after the datehereof.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.